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Background: South Africa has 6.4 million adults over the age of 15 living with HIV. Gender inequality issues
continue to drive the HIV epidemic in South Africa, where Black African women bear the greatest HIV burden.
Limited access to services; little capacity to negotiate sex and condom use; and other legal, social, and economic
inequities make women highly vulnerable to HIV infection. Behavioral interventions have been shown to decrease
risk behaviors, but they have been less successful in reducing HIV incidence. Conversely, biomedical prevention
strategies have proven to be successful in reducing HIV incidence, but require behavioral interventions to increase
uptake and adherence. Consequently, there is a need for integrated approaches that combine biomedical and
behavioral interventions. Effective combination prevention efforts should comprise biomedical, behavioral, and
structural programming proven in randomized trials that focuses on the driving forces and key populations at
higher risk of HIV infection and transmission.
Methods/Design: This prospective, geographically clustered randomized field experiment is enrolling participants
into two arms: a control arm that receives standard HIV testing and referral for treatment; and an intervention arm
that receives an evidence-based, woman-focused behavioral intervention that emphasizes risk reduction and
retention, the Women’s Health CoOp. We divided the city of Pretoria into 14 mutually exclusive geographic zones
and randomized these zones into either the control arm or the intervention arm. Outreach workers are recruiting
drug-using women from each zone. At baseline, eligible participants complete a questionnaire and biological
testing for HIV, recent drug use, and pregnancy. Follow-up interviews are completed at 6 and 12 months.
Discussion: The biobehavioral intervention in this study merges an efficacious behavioral HIV prevention intervention
for women with biomedical prevention through HIV treatment as prevention using a Seek, Test, Treat and Retain
strategy. This combination biobehavioral intervention is designed to (1) improve the quality of life and reduce HIV
infectiousness among women who are HIV positive, and (2) reduce HIV risk behaviors among women regardless of
their HIV status. If efficacious, this intervention could help control the HIV epidemic in South Africa.
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South Africa has the highest number of people living
with HIV in the world. HIV prevalence increased in
South Africa from 10.6% in 2008 to 12.2% in 2012 [1].
This increase likely reflects more accurate estimates
arising from the widespread testing campaigns and a
reduction in HIV-related mortality as a result of the
large-scale expansion of antiretroviral therapy (ART)
programs [2] coupled with continued HIV incidence.
Although the epidemic is generalized, a number of
concentrated subepidemics exist among specific groups
that have HIV prevalence above the national average [3],
including young Black African women and high-risk
alcohol and recreational drug users. A survey by the
South African Human Science Research Council (HSRC)
reported that although the epidemic has stabilized, Black
African women are still the most affected. HIV prevalence
among Black African women aged 15 to 49 is 23.2%,
whereas prevalence among their male counterparts is
18.8% [4]. The HSRC survey also found that among
adults aged 15 to 49, the number of new infections was
1.7 times as high among females as among males.
Moreover, among females aged 15 to 24 the HIV incidence
rate was over four times higher than among males in this
same age group.
Although 37% of men and women between the ages of
15 and 49 have been tested for HIV, testing rates are
much lower among key populations, such as female sex
workers or women who use alcohol or other drugs
(AOD). This is problematic because HIV prevalence
among female sex workers exceeds 50% in some areas
[5], 65% in South Africa, and HIV prevalence among
women who use AOD but are not sex workers is often
greater than 30% [6]. Despite the high prevalence of
HIV, only 60% of female sex workers are reached by
current HIV prevention programs (e.g., HIV testing,
condom distribution) [7]. This relatively low rate of HIV
testing in this key population represents a missed public
health opportunity [8].
Economically disadvantaged women, many of whom
use AOD, are often responsible for supporting them-
selves and their extended families. Under these circum-
stances, they may resort to sex work and engage in high
rates of unprotected sex with multiple partners [9]. A
majority of these partners also have concurrent partner-
ships, which further contributes to the spread of HIV in
South Africa [10]. A study in Ghana found that 84% of
HIV infections among males aged 15 to 59 could be
attributed to transactional sex [11]. In simulation models,
the presence of sex workers led to a substantially larger
heterosexual HIV epidemic. Taken together, the findings
from the epidemiological and modeling studies suggest
that interventions to reduce risk for sex workers could
slow the epidemic [12].Biomedical interventions, such as increasing the per-
centage of people living with HIV that receive ART,
have been associated with reducing HIV transmission
[13]. One meta-analysis of 11 cohort studies of dis-
cordant couples estimated that ART in the index case
resulted in a 92% reduction in HIV incidence [14].
Other studies that examined the effect of HIV treatment
at the community level reported associations between re-
ductions in community viral load and reductions in HIV
incidence [15,16]. These findings suggest that widespread
use of ART can reduce HIV transmission at the commu-
nity level.
ART and other biomedical interventions require
adherence to the medications to be effective. Without
adherence, HIV antiretroviral (ARV) resistance mutations
can occur, leading to loss of viral suppression with risk to
the patients and their sexual partners. Substance abuse
is a critical barrier to ART adherence [17]. Widespread
access to ART may lead to riskcompensation, i.e., an in-
crease in risky behavior caused by actual or perceived
lower risk. Risk compensation occurs when people feel
that they are no longer at risk of HIV infection or trans-
mission [18]. The combined effect of incomplete viral
suppression and risk compensation could potentially
further increase transmission to partners. Consequently,
it is important for biomedical HIV interventions to con-
tinue to emphasize behavioral prevention, particularly
condom use even after initiating ART [19].
While biomedical intervention strategies reduce the
probability of HIV acquisition and transmission, behav-
ioral interventions promote reductions in risk behaviors,
adherence to medications and clinic visits, and condom
use; however, few are specifically gender interventions
focused on women’s issues. In addition, there is growing
recognition that combination interventions with biomed-
ical and evidence-based behavioral strategies coupled with
structural change components—such as increased access
to ART and substance abuse treatment—are more effective
in reducing HIV transmission than any of these strategies
alone [20-22]. Prevention packages that combine effective
woman-focused interventions should be implemented
and scaled up to achieve a measurable reduction in
population-level HIV prevention [23].
Methods/Design
Objectives
The aim of this study is to assess the relative impact of
adding the Women’s Health CoOp (WHC) to standard
Test, Treat, and Retain (TTR) practices on the numbers
of HIV-positive, AOD-using women who receive medical
evaluations (e.g., CD4, viral load), initiate treatment, re-
main in treatment, and have suppressed viral load. It will
also assess the relative impact of adding the WHC to TTR
practices on reductions in risk behaviors (e.g., AOD use,
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regardless of their HIV status.
Study design
This study is a prospective, geographically clustered
randomized two-group field experiment. It is being con-
ducted in 14 geographic clusters in Pretoria, South Africa
(Figure 1). We chose the cluster randomized design to
minimize contamination between study arms. The study
will assess the efficacy of a combined HIV/AIDS preven-
tion/intervention and enhanced strategy targeting AOD-
using women for ART initiation, adherence, retention,
and reduced risk behaviors compared with standard TTR
practices in South Africa. Recruitment started in 2012 and
will end in 2014. Follow-up interviews conducted at 6 and
12 months post-enrollment will continue through 2015.Figure 1 Anticipated recruitment, intervention participation, follow-uSetting
We divided the entire city of Pretoria—which in-
cludes a central business district, other commercial
areas, and residential areas such as a number of for-
mal and informal townships and settlements—into 14
mutually exclusive “zones.” We delineated the zones
according to natural boundaries based on consultation
with outreach workers who were knowledgeable about
Pretoria.
Randomization
We created seven pairs of zones that were matched on
the basis of socioeconomic conditions and estimates of
the number of sex workers and women who use AOD
residing in them. These estimates were based on inputs
from our outreach workers who had worked on one ofp, and allocation of clusters.
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and sex workers in the Pretoria area [23-25].
We randomized zones within each pair to the control
arm or the intervention arm. Each participant’s study arm
is determined by the zone in which she was recruited.
Study population
Participant eligibility criteria include the following: (1)
Female; (2) Black African; (3) Aged 15 or older (if under
18, must be able to demonstrate the criteria for tacit
emancipation according to South African law); (4) Report
using at least one of the following drugs weekly during
the past 90 days—alcohol, marijuana (dagga), metham-
phetamine (tik), methaqualone (Mandrax), cocaine (crack
and/or powder), heroin (Thai White), inhalants (glue
and benzene), MDMA (ecstasy), LSD, methcathinone
(Kat/cat), or marijuana and heroin mixed (Nyaope); (5)
Report having unprotected vaginal sex with a male part-
ner in the past 6 months; (6) Speaks English, Sesotho,
Tswana, or Zulu; (7) Consent to HIV rapid testing and
drug testing; (8) Provide written and verbal assent/consent
to participate; and (9) Provide verifiable locator informa-
tion (e.g., house, street corner, vacant lot) for the Pretoria
area and plan to stay in the area for the next 12 months.
Exclusion criteria include the following: (1) Male; and (2)
Self-identify as other than Black African.
Ethical approval
This study is approved by the South African Medical
Association Research Ethics Committee (SAMAREC),
Tshwane Research Committee (TRC), and the RTI
International Committee for the Protection of Human
Subjects. All participants are required to give their
informed consent prior to any study procedure. We
obtained a waiver for parental consent for participants
under the age of consent, which in South Africa is
18 years. Adolescents aged 12 or older can legally
consent to HIV testing and medical treatment in South
Africa. Also, minors having children, owning a business,
or having an occupation that brings in a salary and
residence outside the parental home are recognized as
emancipated.
When we collect locator information, we explain to
the women that we will be coming to look for them for
their follow-up visits. Outreach workers are trained to
describe the project as a health project, and they are also
trained not to disclose any confidential information. All
of our staff complete ethics training annually.
Data and Safety Monitoring Board
The study has established a Data and Safety Monitoring
Board (DSMB) comprising expert physicians in infectious
diseases, epidemiology, HIV treatment in South Africa,
and bioethics. One physician resides in South Africa andtreats patients, one is a bioethicist, and the chair is also
an infectious disease physician and epidemiologist. The
DSMB receives progress reports and meets biannually
with the investigators and receives notification and in-
formation regarding the circumstances surrounding any
participant deaths.
As specified in our Data and Safety Monitoring Plan
(DSMP), Severe Adverse Events (SAEs) are reported to
the Principal Investigator within 24 hours and to the
DSMB, the funding agency and the Institutional Review




Outreach workers actively market the study in each of
the zones to recruit participants. The outreach model
evolved from a long history of outreach work that started
in North Carolina [26], which was later modified for use
in Pretoria and Cape Town [27,28]. We trained the out-
reach workers on how to market the study in the zones
and how to find female sex workers and other vulnerable
women who use AOD. The training also includes activities
to ensure that outreach workers are aware of safety mea-
sures and how to avoid potentially dangerous situations
they may encounter. Outreach workers conduct outreach
in a wide range of settings that vulnerable women fre-
quent, including daily-rate hotels, taverns, pool halls,
brothels, bushes and thickets, and on street corners.
Outreach workers also market the study to “big mammas”
(madams) and pimps who often serve as gatekeepers for
sex workers.
To enroll in the study, eligible participants travel to
the field site where the baseline appointment takes place.
If participants are not able to come to the field site,
interviews may be conducted in a private setting at or
near the participant’s residence or place of work. In these
instances staff follow a protocol to ensure confidentiality.
All outreach workers are familiar with the city of Pretoria
and fluent in the local languages, and they are trained on
how to approach, screen, and recruit marginalized and
stigmatized vulnerable women.
Modifications to the protocol
Recruitment Originally, we proposed to recruit the
sample by placing mobile units in selected “hotspots” for
both study arms to serve as recruitment venues. The
hotspots are well-known areas in the community. In the
areas randomized to the treatment arm, we planned to
enhance recruitment with active outreach to bring
women to the mobile unit. However, when funding for
the study was awarded, the mobile units were no longer
available. This required us to divide the entire city of
Pretoria into zones. Consequently, outreach workers
Table 1 Modifications to the protocol
Date Amendment
6/2012 Started completing full intake process (i.e., consent,
biological testing, and baseline interview) in the field
in addition to the field site.
6/2012 Dropped recruitment through mobile units and added
recruitment through outreach workers with most activities
conducted at fixed field site. [Note: mobile units were never
used to recruit any participants for the study]
6/2012 Reduced frequency of case management from weekly
to monthly.
11/2012 Changed eligibility criteria from weekly use of 2 or more
drugs (including alcohol) to weekly use of 1 or more drugs
(including alcohol).
12/2012 Provided space onsite to store ARVs for participants who
did not have a place to store them.
10/2013 Reduced proposed sample from 1050 to 600 minimum.
12/2013 Added onsite CD4 testing.
1/2014 Started completing some follow-up interviews in the field
when participants were unable to return to the field site.
5/2014 Increased incentives for baseline interview from R70 to
R100; for 6-month follow-up interviews from R100 to R150;
and for 12-month follow-up interviews from R150 to R200.
[Note: Rand to Dollar conversion rate is approximately
R10 = US $1]
5/2014 Began collecting and storing dried bloodspots for future
HIV viral load testing.
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above and they are brought to a field site in the center
of the city.
Eligibility criteria The original eligibility criteria included
the use of two drugs (one of which could be alcohol)
at least weekly. These criteria excluded a large proportion
of sex workers and other high-risk women, many of
whom were HIV positive. Therefore, we changed eligi-
bility criteria to the use of alcohol or another drug at
least weekly.
Intake process In most instances, staff conduct the in-
take process (i.e., informed consent, baseline interview,
biological testing) at the field site. However, in instances
in which a participant is not able to come into the field
site, project staff conduct the intake in a private setting
in the field.
Intervention case management We initially planned to
conduct case management weekly using cell phones in
most instances. However, many women did not have cell
phones, so staff had to conduct case management face
to face in many instances, which was more labor intensive.
To offset this burden on staff, we reduced the frequency
of case management from weekly to monthly.
Sample size We reduced the sample size from 1050 to
600 minimum. The section on sample size includes a
description of the rationale for this change.
Changes in incentives We increased the incentives for
baseline interviews from R70 to R100 ($1 US equals
approximately 10 Rand). We also increased the incentives
for 6-month follow-up interviews from R100 to R150 and
for 12-month interviews from R150 to R200.
Miscellaneous changes Local HIV clinics required CD4
cell count tests before starting patients on ART. How-
ever, there was a backlog for CD4 testing, which re-
sulted in extensive delays in starting ART. To remove
this barrier, we began providing onsite CD4 testing.
Some women who were on ART reported not having a
secure place to store their ARVs. To alleviate this prob-
lem, we began storing ARVs for women who did not
have a place to store them. We also began conducting
some follow-up interviews in private settings in the field
if a participant could not come to the field site. We
began collecting dried bloodspots for future HIV viral
load testing. This was necessary because many HIV
clinics were unable to provide HIV viral load test re-
sults, and there was no source of viral information for
women who were not in HIV treatment (see Table 1 for
a list of modifications by date).Study activities by arm
Control arm Participants in the control arm receive the
“standard HIV counseling and testing” protocol performed
in South Africa. At intake, participants complete an
interviewer-administered baseline assessment [27]
using Computer-Assisted Personal Interviewing (CAPI)
technology. Project staff collect biological specimens and
test them for evidence of recent drug use, for pregnancy,
and for HIV. They also provide HIV pretest and posttest
counseling. If a participant tests positive for HIV, her post-
test counseling is followed by CD4 testing, which is done
onsite immediately afterward using a PIMA™ analyzer
(http://pimatest.com/en/home.html). In accordance with
medical practice in South Africa, after receiving the CD4
test results, the participant is referred to the appropriate
clinic for further medical evaluation and clinical staging
that determines whether she is eligible to initiate ART
(CD4<350). If the participant initiates ART, she receives
adherence counseling through the health department
clinic and a full battery of tests (blood count, liver func-
tion, and kidney tests) in preparation for ART initiation.
The participant also receives CD4 testing at 6- and 12-
month follow-up visits. HIV-positive people who are
not eligible to receive ART because their CD4 cell
count is >350 are referred to a “wellness program.” The
local health department clinics operate the wellness pro-
grams, which provide access to support groups, ongoing
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productive health, nutrition, and positive living. When
appropriate, the project field staff also provides referrals
for pregnancy services, tuberculosis testing, substance
abuse rehabilitation, and professional counseling for
gender-based violence. Staff members also provide
simple meals and coordinate childcare for women in the
study during their appointments. They also arrange
transportation to the field site for the appointments.
Intervention arm
Women in the intervention arm participate in all of the
activities described above for the control arm. In addition,
they participate in two individual, woman-focused HIV
prevention intervention sessions. These sessions aim to
increase knowledge, skills, and motivation to make behav-
ioral changes related to AOD use, sexual risk, and violence
and victimization. These sessions take place at the field
site and are facilitated by an experienced female interven-
tionist who is a multilingual peer leader from the commu-
nity and who also is sensitive to helping women develop
empowerment strategies with a personalized plan after the
intervention session.
The WHC is an evidence-based, woman-focused, behav-
ioral intervention that reaches high-risk, hard-to-reach,
vulnerable women. It addresses the intersecting risks of
drug use, sex behaviors, violence and victimization, with
the primary goal of increasing skills and knowledge. The
WHC has been adapted from previous iterations in
North Carolina, Rhode Island, Massachusetts, Russia,
the Republic of Georgia, and South Africa. It is based on
social cognitive theory and empowerment theory [29].
Two intervention sessions are held approximately 3 to 5
days apart. Each session lasts 30 to 45 minutes. Key
elements of the sessions educate participants about the
risks of AOD use and how AOD use and sex risk relate
to HIV for women. The sessions also teach risk-reduction
methods such as proper condom use, sexual negotiation,
and violence prevention strategies. Women also role-play
and rehearse how to use male and female condoms cor-
rectly, as well as condom negotiation. During the sessions,
the women create personalized action plans in which they
develop a concrete plan to reduce risk. At the end of the
second session, the participant completes the personalized
plan, which she takes home as a guideline for her set goals.
The staff conducts case management face to face or by cell
phone at least monthly to follow up and support the par-
ticipant in her risk-reduction and action plan to improve
her life. For women with AOD use problems, the inter-
ventionists work closely with drug rehabilitation facilities
to secure treatment slots.
Because this adaptation of the WHC combines TTR
activities with a specific focus on linking women to care
if they are newly or previously diagnosed with HIVbefore enrollment, we named this combined biobehavioral
intervention the Women’s Health CoOp Plus (WHC+).
Outcome measures
The primary outcome is self-reported male or female
condom use during the participant’s most recent episode
of vaginal or anal intercourse. Other outcomes include
frequency of condom use, frequency and quantity of alco-
hol use, urine drug screen results for illicit substance use,
and frequency of violent victimization (physical or sexual).
Additional outcomes for women living with HIV include
receiving HIV treatment, ART adherence, and CD4 counts.
Analyses for HIV-RNA viral load on stored dried blood
spots at follow-up may occur at a later date.
Alcohol use is measured biologically with a breathalyzer
test and through self-report. A biological urine drug
screening test determines recent use of a panel of sub-
stances, including cannabis/marijuana, opioids, cocaine,
methamphetamine, and Mandrax (methaqualone). Vic-
timization includes self-report of being beaten, attacked
with a weapon, or forced to have sex during the previous
90 days. We assess if women living with HIV received
treatment and took ART both biologically and by self-
report. Self-report for ART refers to being prescribed
ART, taking ART if prescribed, and missing any doses in
the past 30 days. We also examine measures of adherence
included in the U.S. National Institute on Drug Abuse’s
harmonization initiative [30]. To help interpret these data,
we also collect self-reports of barriers to ART use.
Staff training and quality assurance
In addition to the outreach training, field staff receive
hands-on training with the Principal Investigator and
with a guided field manual. They also receive ongoing
training and support for the various expressions of emo-
tional distress and crisis management. Interventions and
interviews are audiotaped for quality assurance and all
files are checked by a staff member and then checked
again and signed off by the Field Project Manager.
Training for staff also covers confidentiality and ethics.
All staff members must sign a confidentiality agree-
ment. They are also educated on their responsibilities
for securing the consent forms and screeners and on
the confidentiality requirements of the project.
Data collection, data management, and quality assurance
To protect confidentiality, the study assigns each par-
ticipant a unique study identification code (ID). This
ID is the only link between the behavioral and bio-
logical data and the identifying information collected
for locating participants for their follow-up interviews.
Locator information is stored separately from other
data in a double-locked file cabinet that is in a locked
room with restricted access.
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trained local staff that develop a rapport with the study
participants to engender trust and elicit the most accurate
data possible. Highly trained local interviewers administer
questionnaires using CAPI software that has been pro-
grammed to check that responses to each question are
within the valid range, that responses to different ques-
tions are logically consistent, and to skip questions that
are not applicable. Biological testing information is
keyed into the same software system and rechecked for
accuracy. Data are transmitted each day from the field
site to secure servers at RTI’s headquarters in the
United States. The US-based Data Manager reviews
additional automated quality control checks that the
software generates each day. The Principal Investigator,
other members of the research team, and the field staff
also receive these reports. If any critical inconsistencies
are noted, the Data Manager contacts the Field Project
Manager who works with the field staff member who col-
lected or entered the data to resolve the inconsistency.
Sample size and power
The sample size was lowered to 600 from 1050 as
originally planned. The original sample size was calcu-
lated on the basis of an anticipated HIV prevalence of
30%; however, HIV prevalence in the sample is 55%.
Accordingly, the smaller sample (n = 600) will allow for
the identification of a clinically meaningful effect with
sufficient statistical power, while accounting for logis-
tical difficulties, including a citywide study, limited
structural resources, increased costs, and other factors
outside the control of the study. We assume 14 clus-
ters, approximately 30 observations per cluster and
20% attrition, yielding a final sample size of about 480
respondents at 12-month follow-up. This allows us a
medium to strong likelihood of detecting an effect of
the intervention assuming a strong effect (based on
Cohen’s beta of 0.6). This would translate to an ap-
proximately 10% to 15% difference in the outcomes for
any behavioral outcome (e.g., reductions in AOD use,
number of instances of unprotected sex). We would
not be able to detect mild to weak effects in analyses
that consider the mediation of the effect of the inter-
vention through some cognitive outcome, such as
intentions/self-efficacy/knowledge/gender power. The
reduction in power also greatly reduces the likelihood
of testing whether the intervention yielded modifica-
tion effects across the levels of some covariate and
mediational effects as well. However, we will examine
the distribution of the variables and reestimate power
given the final sample size and variance estimates. No
outcome or mediator/moderator analyses will be con-
ducted unless there is strong power (e.g., Beta greater
than .8, for a 2-tailed test and p = .05).Analysis
We will first conduct descriptive statistical analysis of
baseline variables and clinical characteristics of the
two intervention arms to examine the extent, if any, of
baseline or clinical imbalances between the two arms
using contingency table analyses (Mantel-Haenszel for
categorical and analysis of variance for continuous
variables). The analysis will center around estimating
the impact of the intervention on each of the primary
study outcomes, observed at baseline and 6- and 12-
month follow-up visits, using all available cases con-
sistent with an intent-to-treat method. In addition to
evaluating changes in each outcome by intervention
arm at 6-month follow-up, the analysis will examine
whether the changes are sustained or decay at 12-month
follow-up. Given the longitudinal nature of the data, our
primary analytic strategy will apply a generalized estimat-
ing equation (GEE) modeling approach to account for the
multiple dependencies of repeated measures collected on
the same individuals over time, and the clustering of the
outcomes by community. Because the communities may
range from 5 to 100 cases, the generalized linear/nonlinear
mixed model (e.g., hierarchical linear modeling or multi-
level modeling with random effects) would likely face
problems with convergence given the heterogeneity in
the variation between communities. Therefore, we opt
for a statistical strategy that treats this level of clustering
as a nuisance parameter, and thereby estimating the
population-averaged effects of the outcomes for subjects
sharing the same profile of individual and community-
level characteristics. For outcomes with binomial or
count distributions, the logit link will be specified to
obtain effect estimates of the magnitude of differences
between arms within each follow-up visit. For continu-
ously distributed outcomes, an identity link function
will be specified. We expect that we will estimate the
working correlation matrix at the temporal level using a
first-order autoregressive structure (AR-1) and an ex-
changeable correlation matrix at the community-level,
thereby allowing the subjects within each cluster to be
constrained to equality but freeing the estimates between
clusters.
In addition to the main outcome analyses, we will
examine the mechanism of change via standard media-
tional models. For this approach, we will lag the time-
points such that the baseline will be the most
exogenous, then the midpoint 6-month observation
will be the mediator and the 12-month observation will
serve as the distal outcome. We can also estimate a
mediational model with two timepoints, estimating the
distal outcome at 6 months along with the concurrent me-
diator. These models will be fit using standard structural
equation modeling software packages (e.g., Mplus), which
can adjust the standard errors via bootstrapping to reduce
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These models can be estimated using a mixture of dis-
tributions, such as a categorical mediator or outcome
in concert with a continuously distributed mediator or
outcome. The mediational analyses will address the
extent to which the intervention worked and estimate
the direct and indirect mechanisms. However, modera-
tional analyses will address the extent to which the
intervention worked for specific subgroups, such as
women who are HIV positive, women in a relationship,
and women with a criminal history. For these analyses,
interaction terms will be created by multiplying the
effect of the intervention by the moderator variable of
interest.
Discussion
Behavioral and biomedical interventions typically involve
separate research silos. This project bridges these fields
with a biobehavioral intervention that aims to reduce
risk behavior and victimization and improve HIV-related
clinical outcomes. This blend of biological and behavioral
outcomes, which we assess using biological tests and self-
reports, will help to inform how to further enhance the
use of women-centered interventions in clinical settings.
This study comprises four important innovations: (1) a
citywide outreach component to increase the number of
high-risk women reached; (2) an intervention case man-
agement component to increase HIV treatment initiation
and retention in women who test positive for HIV; (3)
evidence-based, gender-focused behavioral counseling to
reduce risk behavior and increase ART adherence among
women who are HIV positive; and (4) evidence-based
risk-reduction counseling for women who are HIV nega-
tive. This last innovation is especially important in a coun-
try like South Africa with high HIV prevalence, where
even people who exhibit a low level of risk behavior are
nonetheless likely to be exposed to HIV.
The urine drug screens, HIV viral load tests, and CD4
cell count tests strengthen the scientific rigor of the
study. Using biologically confirmed outcomes in addition
to self-report will increase confidence in the findings
regarding intervention efficacy. The new protocol for the
WHC in this study has enhanced the intervention by
integrating biomedical elements into the empowerment
intervention to produce a combination of biobehavioral
outcomes. This combination of outcomes will increase the
efficacy of the intervention and improve our understand-
ing of women’s vulnerability.
Studies show that HIV testing alone has little impact
on risk behavior among people who test negative for
HIV [31,32]. Combining the WHC with the current test,
treat, and retain activities can potentially increase the effi-
ciency of the TTR strategy substantially. The combination
prevention approach ensures that women who are HIVnegative receive the WHC intervention, which has
been shown to reduce HIV risk behavior [25,28]. The
combination approach also links women who are HIV
positive to treatment, and supports their retention in
treatment through case management. If this combination
approach demonstrates efficacy, the WHC component is
already packaged and ready for rapid implementation in
real-world settings, which increases the likelihood that it





AOD: Alcohol or other drug; ART: Antiretroviral therapy; AR-1: First-order
autoregressive structure; CAPI: Computer-Assisted Personal Interviewing;
DSMB: Data and Safety Monitoring Board; DSMP: Data and Safety Monitoring
Plan; GEE: Generalized estimating equation; HSRC: South African Human
Science Research Council; SAEs: Severe Adverse Events; SAMAREC: South
African Medical Association Research Ethics Committee; STTR: Seek, test,
treat, and retain; TRC: Tshwane Research Committee; TTR: Standard test, treat,
and retain; WHC: Women’s Health CoOp; WHC+: Women’s Health CoOp Plus.
Competing interests
The authors declare that there are no competing interests.
Authors’ contributions
WW conceived the study and finalized the manuscript. WZ helped develop
the manuscript and finalize it. JN wrote the background. TK, RN, ID and SN
contributed to the methods and CVDH added to the final protocol. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank Jeffrey Novey for editorial assistance. This study was
supported by U.S. National Institute on Drug Abuse (NIDA) grant
R01DA032061. We would also like to thank Sergio Carmona of National
Health Laboratory Service for help with the PIMA™ system and dried
blood spot training, Wesley Community Centre, and the study
participants. The views and conclusions are those of the authors and do
not necessarily reflect the views of NIDA. The funding agency had no role
in the research design or the protocol development, or in suggesting
publication plans for this article.
Author details
1RTI International, 3040 E. Cornwallis Road, PO Box 12194, Research Triangle
Park, NC 27709-2194, USA. 2RTI International, 258 Burgers Park Lane, Pretoria,
South Africa. 3UNC Chapel Hill School of Medicine, Manning Drive, Chapel
Hill, NC 27599-7030, USA.
Received: 27 September 2014 Accepted: 2 October 2014
Published: 15 October 2014
References
1. UNAIDS: Global report: UNAIDS report on the global HIV/AIDS epidemic 2013.
Geneva: UNAIDS; 2013.
2. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, Carrara H, Jooste
S: A decline in new HIV infections in South Africa: estimating HIV
incidence from three national HIV surveys in 2002, 2005 and 2008.
PLoS One 2010, 5(6):e11094.
3. Tanser F, de Oliveira T, Maheu-Giroux M, Barnighausen T: Concentrated HIV
subepidemics in generalized epidemic settings. Curr Opin HIV AIDS 2014,
9(2):115–125.
4. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Zungu N, Labadarios D,
Onoya D: South African National HIV Prevalence, Incidence and Behaviour
Survey, 2012. Cape Town: HSRC Press; 2014.
Wechsberg et al. BMC Public Health 2014, 14:1074 Page 9 of 9
http://www.biomedcentral.com/1471-2458/14/10745. Papworth E, Ceesay N, An L, Thiam-Niangoin M, Ky-Zerbo O, Holland C,
Drame FM, Grosso A, Diouf D, Baral SD: Epidemiology of HIV among
female sex workers, their clients, men who have sex with men and
people who inject drugs in West and Central Africa. J Int AIDS Soc 2013,
16 Suppl 3:18751.
6. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M,
Madlala BT, Ntombela F, Abdool Karim SS: Stabilizing HIV prevalence
masks high HIV incidence rates amongst rural and urban women in
KwaZulu-Natal, South Africa. Int J Epidemiol 2011, 40(4):922–930.
7. Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV
transmission: how to make them work better. Lancet 2008, 372(9639):669–684.
8. Republic of South Africa: Country Progress Report on the Declaration of
Commitment on HIV/AIDS Reporting Period: January 2008 - December
2009; Final Report. 2010, March 31, 2010, Republic of South Africa.
9. Shannon K, Strathdee SA, Goldenberg SM, Duff P, Mwangi P, Rusakova M,
Reza-Paul S, Lau J, Deering K, Pickles MR, Boily MC: Global epidemiology of
HIV among female sex workers: influence of structural determinants.
Lancet, 13–29. HIV and Sex Worker Supplement, July, 2014.
10. Lowndes CM, Alary M, Labbe AC, Gnintoungbe C, Belleau M, Mukenge L, Meda
H, Ndour M, Anagonou S, Gbaguidi A: Interventions among male clients of
female sex workers in Benin, West Africa: an essential component of
targeted HIV preventive interventions. Sex Transm Infect 2007, 83(7):577–581.
11. Cote AM, Sobela F, Dzokoto A, Nzambi K, Asamoah-Adu C, Labbe AC, Masse
B, Mensah J, Frost E, Pepin J: Transactional sex is the driving force in the
dynamics of HIV in Accra, Ghana. AIDS 2004, 18(6):917–925.
12. Mukandavire Z, Garira W: Effects of public health educational campaigns
and the role of sex workers on the spread of HIV/AIDS among
heterosexuals. Theor Popul Biol 2007, 72(3):346–365.
13. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, McIntyre J,
Lingappa JR, Celum C: Heterosexual HIV-1 transmission after initiation of
antiretroviral therapy: a prospective cohort analysis. Lancet 2010,
375(9731):2092–2098.
14. Attia S, Egger M, Muller M, Zwahlen M, Low N: Sexual transmission of HIV
according to viral load and antiretroviral therapy: systematic review and
meta-analysis. AIDS 2009, 23(11):1397–1404.
15. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN:
Decreases in community viral load are accompanied by reductions in
new HIV infections in San Francisco. PLoS One 2010, 5(6):e11068.
16. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, Harrigan PR, Montaner
JS: Longitudinal community plasma HIV-1 RNA concentrations and
incidence of HIV-1 among injecting drug users: prospective cohort
study. BMJ 2009, 338:b1649.
17. Sandelowski M, Voils CI, Chang Y, Lee E-J: A systematic review comparing
antiretroviral adherence descriptive and intervention studies conducted
in the USA. AIDS Care 2009, 21(8):953–966.
18. Eaton LA, Kalichman S: Risk compensation in HIV prevention: implications
for vaccines, microbicides, and other biomedical HIV prevention
technologies. Curr HIV/AIDS Rep 2007, 4(4):165–172.
19. Venkatesh KK, Flanigan TP, Mayer KH: Is expanded HIV treatment
preventing new infections? Impact of antiretroviral therapy on sexual
risk behaviors in the developing world. AIDS 2011, 25(16):1939–1949.
20. Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD: Antiviral agents
and HIV prevention: controversies, conflicts, and consensus. AIDS 2012,
26(13):1585–1598.
21. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr: Biomedical
interventions to prevent HIV infection: evidence, challenges, and way
forward. Lancet 2008, 372(9638):585–599.
22. UNAIDS: Combination HIV prevention: Tailoring and coordinating biomedical,
behavioural and structural strategies to reduce new HIV infections. Geneva:
UNAIDS; 2010.
23. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN: Combination
HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS
Rep 2011, 8(1):62–72.
24. Wechsberg WM, Luseno WK, Kline TL, Browne FA, Zule WA: Preliminary
findings of an adapted evidence-based woman-focused HIV intervention
on condom use and negotiation among at-risk women in Pretoria, South
Africa. J Prev Interv Community 2010, 38(2):132–146.
25. Wechsberg WM, Zule WA, Luseno WK, Kline TL, Browne FA, Novak SP,
Ellerson RM: Effectiveness of an adapted evidence-based woman-focused
intervention for sex workers and non-sex workers: the Women's Health
CoOp in South Africa. J Drug Iss 2011, 41(2):233–252.26. Wechsberg WM, Smith FJ, Harris-Adeeyo T: AIDS education and outreach
to IV drug users and the community: strategies and results. Psychol Addict
Behav 1992, 6(Special Issue on AIDS and Substance Abuse):107–113.
27. Wechsberg WM, Luseno WK, Lam WK: Violence against substance-abusing
South African sex workers: intersection with culture and HIV risk. AIDS
Care 2005, 17(Suppl 1):S55–64.
28. Wechsberg WM, Luseno WK, Lam WK, Parry CD, Morojele NK: Substance
use, sexual risk, and violence: HIV prevention intervention with sex
workers in Pretoria. AIDS Behav 2006, 10(2):131–137.
29. Wechsberg WM: Facilitating empowerment for women substance
abusers at risk for HIV. Pharmacol Biochem Behav 1998, 61(1):158.
30. Data harmonization projects. Seek, test, treat, and retain. [http://www.
drugabuse.gov/researchers/research-resources/data-harmonization-projects]
31. Cawley C, Wringe A, Slaymaker E, Todd J, Michael D, Kumugola Y, Urassa M,
Zaba B: The impact of voluntary counselling and testing services on
sexual behaviour change and HIV incidence: observations from a cohort
study in rural Tanzania. BMC Infect Dis 2014, 14:159.
32. Fonner VA, Denison J, Kennedy CE, O'Reilly K, Sweat M: Voluntary
counseling and testing (VCT) for changing HIV-related risk behavior in
developing countries. Cochrane Database Syst Rev 2012, 9:Cd001224.
doi:10.1186/1471-2458-14-1074
Cite this article as: Wechsberg et al.: The biobehavioral Women’s Health
CoOp in Pretoria, South Africa: study protocol for a cluster-randomized
design. BMC Public Health 2014 14:1074.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
